WCLC 2023 | Evaluating the cost-effectiveness of radiotherapy for lung cancer in Australia

Shalini Vinod, MBBS, University of New South Wales, Sydney, Australia, discusses the cost-effectiveness for the treatment of lung cancer. Previous research concluded that radiotherapy improved 5-year local control of lung cancer and in a study conducted by an Australian public radiotherapy department, the average cost of radiotherapy with a 1-year local control benefit was lower for stage I/II lung cancer than for stage III/IV lung cancer. The costs of radiotherapy per 1-year survival benefit were revealed to be below the accepted cost-effectiveness threshold (AU$ 50,000 per year life gained) for stage I/II lung cancer and for stage III lung cancer. Dr Vinod concluded that radiotherapy is inexpensive and cost-effective in the treatment of lung cancer. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.